**Table 4: Monoclonal antibody infusion reactions: incidence and management**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Any infusion reaction** | **Severe infusion reaction** | **Pre-medication prior to 1st dose** | **Rechallenge success** | **Rapid desensitization protocol** |
| **Rituximab (PI)** | Majority of patients | 10% | Acetaminophen and antihistamine | Yes, decrease next infusion rate by 50% once symptoms resolve | Yes |
| **Cetuximab (PI)** | 12% | 2-5% | Diphenhydramine | For grade 1-2 or non-serious Grade 3 or 4, decrease infusion rate by 50% upon symptom resolution | Yes |
| **Trastuzumab** | 40% | <1% | No | Decrease infusion rate by 50% | Yes |
| **Panitumumab** | 3% | 1% | No | Decrease infusion rate by 50% | No |